TerminatedPhase 3ACTRN12616000311459

Melatonin to improve induction of labour: a double blind, randomised, placebo controlled trial.

A double blind, randomised, placebo controlled trial to evaluate the effect of Melatonin as an adjuvant agent at Induction of labour on the rate of induction of labour failure in healthy, pregnant women undergoing cervical ripening prior to induction of labour for prolonged pregnancy


Sponsor

Monash Health

Enrollment

722 participants

Start Date

Mar 28, 2019

Study Type

Interventional

Conditions

Summary

Induction of labour is a common obstetric intervention that 1 in 4 women will experience. The ultimate goal of induction of labour is to achieve a vaginal birth, however in almost 40% of first time mothers it fails. The outcome of a failed induction, a caesarean delivery is associated with vast range of adverse effects, both short and long term for the mother and her baby. In this application we propose that a simple and inexpensive intervention will increase the success of induction of labour. Lessons from successful spontaneous births tell us that labour occurs more frequently, and is shorter with less intervention when it occurs at night. The driver of this is thought to be the endogenous hormone, melatonin. Melatonin is synthesised by the placenta. Healthy pregnant women have higher concentrations of melatonin compared to non-pregnant women. Melatonin levels also increase with gestation, peaking during labour and then falling rapidly after delivery. The biological reason for an altered melatonin cycle in pregnancy is unclear. However, the myometrium of the pregnant uterus expresses melatonin receptors and these receptors have been shown to be up-regulated in labouring compared to non-labouring women. Intriguingly, both melatonin and oxytocin activate the same signalling pathway that results in uterine contractions. Specifically, melatonin treatment of myometrium increases it’s sensitivity, enhances oxytocin-induced contractions and improves myometrium cell communication and synchronization. Taken together this suggests an important role of melatonin in the onset and progress of labour. We therefore hypothesise that supplementing women undergoing induction of labour with melatonin will improve the success rate of induction of labour. We will undertake a double-blinded randomised controlled trial of melatonin supplementation to improve the success of induction of labour in healthy first time mothers.


Eligibility

Sex: FemalesMin Age: 18 YearssMax Age: 49 Yearss

Inclusion Criteria3

  • Pregnant women, parity: 0 (nulliparous) or up to para 3 (multiparous), who currently have a singleton, cephalic presentation undergoing induction of labour for prolonged pregnancy with a low Bishop score (a score of cervical ripeness) of 5 or less.
  • Methods of cervical ripening/labour induction to include: cervical balloon catheter e.g. Foley, Cook, Atad and/or a Dinoprostone PGE 2 vaginal pessary e.g. Cervadil or Prostin or women who are only having an amniotomy as the initial method of labour induction.
  • Intact membranes. No known significant maternal or obstetric medical condition that would affect melatonin pharmacokinetics or maternal safety. The woman must be able to provide written informed consent to participate in the clinical trial

Exclusion Criteria1

  • Non-reassuring fetal status (e.g. diminished or no fetal movements, non-reassuring CTG, known lethal fetal congenital anomalies or abnormal karyotype, fetal growth restriction (FGR) 10th centile or less, with Doppler changes), a clinical decision indicative of a low threshold for caesarean section, contraindication to a cervical ripening balloon catheter (as per Monash Health CPG IOL Cervical Ripening balloon catheter procedure. Prompt Doc No: SNH0003541 v3.0), known allergy or sensitivity to melatonin or any of the excipients in its formulation, unwillingness or inability to follow the procedures outlined in the PI&CF, mentally, cognitively or legally incapacitated or unable to provide informed consent, co-recruitment/participation in another clinical trial where there is pharmaceutical or herbal or nutritional intervention (such trial interventions would also include: multi-vitamins, minerals, complementary and alternative medicines), currently taking a medication known to influence melatonin pharmacokinetics or bioavailability.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

The intervention for this trial is:: melatonin (10mg) prolonged release (Circadin), oral tablet. We propose to administer the trial intervention (melatonin 10mg prolonged release) or a comparator,

The intervention for this trial is:: melatonin (10mg) prolonged release (Circadin), oral tablet. We propose to administer the trial intervention (melatonin 10mg prolonged release) or a comparator, a placebo, oral tablet. There are TWO trial tablet administration regimens. The trial tablet administration regimen will be determined by the method of cervical ripening/labour induction, the tablet administration regimens are as follows: For those women who are having a cervical balloon catheter and/or vaginal Dinoprostone PGE 2 (e.g Cervadil or Prostin) as the initial method of labour induction: 1) The first dose of the tablets will be given at the time of the initial cervical balloon catheter or vaginal Dinoprostone PGE 2 insertion 2) The second dose of tablets will be given after the membranes ('waters') are broken and only when the oxytocin intravenous infusion (IVI) is started (within 30 minutes) 3) Six hours after the second dose, if birth has not yet occurred, a third dose of tablets will be given 4) Six hours after the third dose, if birth has not yet occurred, a fourth and final dose of tablets will be given. For this group of participants, if birth occurs at any time between the first and fourth dose, administration of the trial tablets will immediately cease. For those women who are just having amniotomy as the initial method of labour induction: 1) The first dose of the trial tablets will be given after the amniotomy procedure and only when the oxytocin intravenous infusion (IVI) is started (within 30 minutes) 2) Six hours later, if birth has not occurred, a second dose of tablets will be given 3) Six hours after the second dose, if birth has not yet occurred, a third and final dose of tablets will be given. For this group of participants, if birth occurs at any time between the first and third dose, administration of the trial tablets will immediately cease.


Locations(1)

Monash Medical Centre - Clayton campus - Clayton

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12616000311459